These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 33333889)

  • 1. Preliminary Results of the FASM Study, an On-Going Italian Active Pharmacovigilance Project.
    Maniscalco GT; Brescia Morra V; Florio C; Lus G; Tedeschi G; Cianfrani M; Docimo R; Miniello S; Romano F; Sinisi L; Spitaleri DLA; Longo G; Trama U; Triassi M; Fasm Group ; Scavone C; Capuano A
    Pharmaceuticals (Basel); 2020 Dec; 13(12):. PubMed ID: 33333889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse Drug Reactions with Drugs Used in Multiple Sclerosis: An Analysis from the Italian Pharmacovigilance Database.
    Barbieri MA; Sorbara EE; Battaglia A; Cicala G; Rizzo V; Spina E; Cutroneo PM
    Front Pharmacol; 2022; 13():808370. PubMed ID: 35281926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Safety Profile of General and Local Anaesthetic Agents: Data Collected during 20 Years of Spontaneous Reporting Activities in the Campania Region (Southern Italy).
    Gargano F; Scavone C; di Mauro G; Corte AD; Zoccoli A; Rossi F; Nicoletti GF; Capuano A
    Pharmaceuticals (Basel); 2021 Dec; 14(12):. PubMed ID: 34959662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe Cutaneous Adverse Drug Reactions Associated with Allopurinol: An Analysis of Spontaneous Reporting System in Southern Italy.
    Scavone C; Di Mauro C; Ruggiero R; Bernardi FF; Trama U; Aiezza ML; Rafaniello C; Capuano A
    Drugs Real World Outcomes; 2020 Mar; 7(1):41-51. PubMed ID: 31848905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacovigilance in ophthalmology in Switzerland: an analysis of the most frequently reported ocular adverse drug reactions within the last 25 years.
    Karrer JE; Giovannoni L; Kullak-Ublick GA; Weiler S
    Swiss Med Wkly; 2019 Jun; 149():w20085. PubMed ID: 31256417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatobiliary Adverse Reactions during Treatment with Cladribine: Analysis of Data from the European Spontaneous Reporting System.
    Velișcu EM; Liguori V; Anatriello A; Maniscalco GT; Cantone A; Di Costanzo L; Stefanelli P; Scavone C; Capuano A
    Pharmaceuticals (Basel); 2023 Jul; 16(8):. PubMed ID: 37630986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real World Data on the Utilization Pattern and Safety Profile of Infliximab Originator Versus Biosimilars in Italy: A Multiregional Study.
    Scavone C; Sessa M; Clementi E; Corrao G; Leone R; Mugelli A; Rossi F; Spina E; Capuano A
    BioDrugs; 2018 Dec; 32(6):607-617. PubMed ID: 30341487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Global Versus Indian Perspective of Pioglitazone-induced Adverse Drug Reactions Including Bladder Cancer: A Comparative Retrospective Pharmacovigilance Analysis.
    Bhushan S; Ray RS; Prakash J; Singh GN
    Clin Ther; 2019 Nov; 41(11):2252-2262. PubMed ID: 31543285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral disease-modifying therapies for relapsing-remitting multiple sclerosis.
    Thomas RH; Wakefield RA
    Am J Health Syst Pharm; 2015 Jan; 72(1):25-38. PubMed ID: 25511835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of Antiplatelet Agents: Analysis of 'Real-World' Data from the Italian National Pharmacovigilance Network.
    Gozzo L; Navarria A; Benfatto G; Longo L; Mansueto S; Sottosanti L; Pani L; Salomone S; Drago F
    Clin Drug Investig; 2017 Nov; 37(11):1067-1081. PubMed ID: 28856572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Social Impact of Suspected Adverse Drug Reactions: An analysis of the Canada Vigilance Spontaneous Reporting Database.
    Castillon G; Salvo F; Moride Y
    Drug Saf; 2019 Jan; 42(1):27-34. PubMed ID: 30121742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
    Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of age, sex and seriousness on reporting of adverse drug reactions in Sweden.
    Holm L; Ekman E; Jorsäter Blomgren K
    Pharmacoepidemiol Drug Saf; 2017 Mar; 26(3):335-343. PubMed ID: 28071845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The changing multiple sclerosis treatment landscape: impact of new drugs and treatment recommendations.
    Eriksson I; Komen J; Piehl F; Malmström RE; Wettermark B; von Euler M
    Eur J Clin Pharmacol; 2018 May; 74(5):663-670. PubMed ID: 29429031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison.
    Hutchinson M; Fox RJ; Havrdova E; Kurukulasuriya NC; Sarda SP; Agarwal S; Siddiqui MK; Taneja A; Deniz B
    Curr Med Res Opin; 2014 Apr; 30(4):613-27. PubMed ID: 24195574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacovigilance in Israel - tools, processes, and actions.
    Schwartzberg E; Berkovitch M; Dil Nahlieli D; Nathan J; Gorelik E
    Isr J Health Policy Res; 2017 Aug; 6(1):29. PubMed ID: 28760141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse drug reactions in Nigerian children: a retrospective review of reports submitted to the Nigerian Pharmacovigilance Centre from 2005 to 2012.
    Obebi Cliff-Eribo K; Sammons H; Star K; Ralph Edwards I; Osakwe A; Choonara I
    Paediatr Int Child Health; 2016 Nov; 36(4):300-304. PubMed ID: 26384567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis.
    Granqvist M; Boremalm M; Poorghobad A; Svenningsson A; Salzer J; Frisell T; Piehl F
    JAMA Neurol; 2018 Mar; 75(3):320-327. PubMed ID: 29309484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse drug reactions at adverse drug reaction monitoring center in Raipur: Analysis of spontaneous reports during 1 year.
    Singh P; Agrawal M; Hishikar R; Joshi U; Maheshwari B; Halwai A
    Indian J Pharmacol; 2017; 49(6):432-437. PubMed ID: 29674797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.